A. Lee
Bristol-Myers Squibb (United Kingdom) · 3 works · 49 citations · h-index 2
Top works
- Primary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/− bevacizumab, with or without atezolizumab in 1L non-squamous metastatic nsclc (IMPOWER150)
- OA09.06 Health-Related Quality of Life (HRQoL) Outcomes with Adagrasib vs Docetaxel in KRASG12C-Mutated Advanced NSCLC in KRYSTAL-12
- IMpower150: analysis of efficacy in patients (pts) with liver metastases (mets)